All News

Found 318 articles

• Cancer Monoclonal Antibodies Market Worth USD 159.8 BN By 2030 | CAGR: 11.4%

  11/14/2022

  According to Nova one advisor's recent analyses the Cancer Monoclonal Antibodies Market is valued at USD 62.4 Billion in 2021, and would all set to rocket up to USD 159.8 Billion by 2030, at a CAGR of 11.4% during the forecast period from 2022 to 2030

• Biopharmaceutical CMO and CRO Market Size, Share, Report 2022 to 2030

  11/11/2022

  As per Precedence Research, the global biopharmaceutical CMO and CRO market size is predicted to surpass US$ 59.13 billion by 2030 and growing at a CAGR of 7.4% from 2022 to 2030.

• Microcarriers Market Size, Share | Report 2022-2030

  11/10/2022

  According to Latest Report Study, the global microcarriers market was valued at USD 1.27 billion in 2021 and it is predicted to surpass around USD 3.32 billion by 2030 with a CAGR of 11.27% from 2022 to 2030.

• Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

  11/7/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2022.

• Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

  11/2/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets.

• Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

  11/1/2022

  Incyte (Nasdaq:INCY) today reports 2022 third quarter financial results, and provides a status update on the Company’s clinical development portfolio.

• 

  FDA's ODAC Unanimously Votes against Y-mAbs' Pediatric Neuroblastoma Treatment

  10/28/2022

  The FDA's Oncologic Drugs Advisory Committee voted unanimously against approving l-omburtamab for children with a rare form of neuroblastoma, citing complex review issues.

• Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

  10/28/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

• New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

  10/26/2022

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Oct. 26-28 in Amsterdam.

• Custom Antibody Market Size USD 833.96 Million by 2030 | CAGR of 8.23%

  10/25/2022

  The global custom antibody market was valued at USD 409.31 million in 2021 and it is predicted to surpass around USD 833.96 million by 2030 with a CAGR of 8.23% from 2022 to 2030.

• MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services

  10/4/2022

  MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector has opened a commercial facility for its new Millipore® CTDMO Services offering at the company's site in Martillac, France.

• Y-mAbs Announces Pivotal Data for Omburtamab

  10/3/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

• Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

  9/26/2022

  Y-mAbs Therapeutics, Inc. today announced that Adium Pharma S.A. (“Adium”) has submitted a regulatory filing for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

• Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

  9/20/2022

  Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody -based drug product prototypes targeting plague.

• Rise in Prevalence of Disease and Increase in Cancer-Causing is Expected to Drive Neuroblastoma Market Growth by 2030 | Reports and Data

  9/16/2022

  The latest market analysis report published by Reports and Data, titled ‘Global Neuroblastoma Market – Forecast to 2030,’ thoroughly examines the Neuroblastoma industry to provide essential data & information for the targeted readers.

• Custom Antibody Market: Increasing Incidences of Infectious Diseases to Drive the Market

  9/13/2022

  Antibodies are defined as the host proteins created by human body as a reaction after the entry of foreign molecules or foreign bodies in the body.

• Infertility Testing and Treatment Market Insights and Emerging Trends by 2031

  9/2/2022

  Wilmington, Delaware, United States, Transparency Market Research Inc. – Infertility is defined as the inability to conceive naturally after one year of unprotected copulation.

• Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

  9/1/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), today announced that a meeting of the Oncologic Drugs Advisory Committee (“ODAC”) of the U.S. Food and Drug Administration (“FDA”) has been scheduled for October 28, 2022 to review the Company’s Biological License Application (“BLA”) for its product candidate, OMBLASTYS® (omburtamab), an investigational radiolabeled antibody construct.

• Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

  8/30/2022

  Y-mAbs Therapeutics, Inc. and Takeda Israel, announced today that the Israeli Ministry of Health has approved DANYELZA in Israel for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

• Stomach Cancer Treatment Market Size, Share, Trends, Report 2022 to 2030

  8/29/2022

  The global stomach cancer treatment market was estimated at USD 3.94 billion in 2021 and is expected to hit around USD 11.5 billion by 2030, growing at a CAGR of 12.64% from 2022 to 2030.